COGT Latest Press Releases

-- October 27, 2026 --

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference Globe Newswire 4:01 PM

-- September 15, 2026 --

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) Globe Newswire 8:00 AM

-- August 10, 2026 --

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- June 30, 2026 --

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) Globe Newswire 8:00 AM

-- June 12, 2026 --

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress Globe Newswire 8:01 AM

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress Globe Newswire 8:00 AM

-- May 30, 2026 --

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes